Digital Care Leader's Integrated Program Supports Individuals Dealing with Chronic Disease, Mental Health Issues

SAN FRANCISCO, June 26, 2019 /PRNewswire/ -- Omada Health today announced a $73 million round of funding led by Wellington Management Company LLP. Wellington Management is an independent investment firm with more than $1 trillion of client assets under management. Omada will use the funding to fuel the continued expansion of its digital care program, including support for those with type 2 diabetes and hypertension, as well as those dealing with anxiety and depression.

Omada works with more than 600 employers and health plans across all 50 states, delivering an integrated experience that adapts to participants' health needs, and personalizes their journeys to create the best health outcomes. Omada's dedicated coaches guide each individual throughout the program, achieving unparalleled engagement and sustainable behavior change. Omada's proprietary coaching platform enables them to deliver personalized interventions at scale. The company proved the model for digital care as the nation's largest CDC-recognized provider of the National Diabetes Prevention Program, and has now launched programs over the last twelve months for diabetes self-management, as well as anxiety and depression, to holistically address individuals' health needs.

Read More: https://www.prnewswire.com/news-releases/omada-health-raises-73-million-to-accelerate-program-expansion-300874939.html

-- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening --

SAN FRANCISCO, June 17, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS).

"Since we began, Invitae has invested deeply to harness the power of the most advanced genetic testing technologies in order to deliver expert-level genetic information at scale, and bringing this company into Invitae is the next step in that process," said Sean George, PhD, co-founder and chief executive officer of Invitae. "Singular Bio is building an approach to non-invasive prenatal screening with the potential to achieve the cost savings necessary to provide more women with genetic information to support a healthy pregnancy. We believe this approach could eventually be applied to other areas of genetic testing. The addition of Singular Bio's technology will further strengthen our ability to bring genetic information into mainstream medical care."

Read More: https://www.prnewswire.com/news-releases/invitae-to-acquire-singular-bio-to-help-increase-access-to-genetic-screening-in-early-pregnancy-300869252.html

Vikram S Kashyap, co-principal investigator of the ROADSTER 2 trial, today presented the final 30-day outcomes of the post-market approval study in a late-breaking trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 12–15 June, National Harbor, USA). The data show the sustained safety and efficacy of transcarotid artery revascularisation (TCAR) with Silk Road Medical’s Enroute system. In this interview, Kashyap speaks to Vascular News about the procedure, and how TCAR trialists are hoping to make an impact for patients needing carotid revascularisation.

What is the idea behind TCAR, and how does it differ from carotid endarterectomy or transfemoral carotid stenting?
Transcarotid artery revascularisation is very different to other treatment strategies, such as carotid endarterectomy [CEA] or stenting [CAS]. This is a carotid stenting procedure, but it is via a different approach—a transcarotid approach—and the critical issue is that there is a protection mechanism to prevent cerebral embolisation which is using an extracorporeal reversal flow system, and importantly, clamping of the carotid artery below the sheath insertion that leads to obligate reversal flow in the carotid system during the intervention. So, this is very different to transfemoral CAS in that one does not have to navigate the aortic arch and the carotid arteries to get the devices there.

Read More: https://vascularnews.com/final-results-of-the-roadster-2-post-market-approval-study-of-tcar-interview-with-vikram-s-kashyap/

Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting

NATIONAL HARBOR, Md., June 15, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive final results for the company’s ROADSTER-2 post-marketing study evaluating real world use of the ENROUTE® Neuroprotection and Stent Systems in TransCarotid Artery Revascularization (TCAR) procedures.

In the late-breaking session at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), Dr. Vikram Kashyap, Chief of Vascular Surgery and Endovascular Therapy at University Hospitals Case Medical Center (Cleveland, OH) and National Co-Principal Investigator of ROADSTER-2, reported that the study demonstrated compelling patient outcomes with low stroke and combined stroke and death rates of 0.6% and 0.8%, respectively, in 632 high surgical risk patients enrolled across 42 sites. Seventy percent (70%) of patients enrolled in the study were from physicians new to TCAR.

Read More: https://www.globenewswire.com/news-release/2019/06/15/1869294/0/en/ROADSTER-2-Demonstrates-Compelling-Patient-Outcomes-with-Strong-Safety-Profile.html

NATIONAL HARBOR, Md., June 13, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM). In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project.

The results of the TCAR Surveillance Project are overwhelmingly positive on a large dataset of patients, showing, for the first time, significantly lower odds of composite in-hospital stroke, death and myocardial infarction compared to CEA. TCAR had statistically equivalent in-hospital stroke and death rates as CEA, with significantly lower odds of myocardial infarction and cranial nerve injury. Additionally, there was a significant reduction in mortality at 30 days and 1 year, likely attributable to the reduction in myocardial infarction,” Dr. Malas said. “Patients clearly benefit from TCAR’s less-invasive approach and with these data and future studies with similar results, I believe TCAR may become the standard of care.”

Read More: https://www.globenewswire.com/news-release/2019/06/13/1868408/0/en/TCAR-Achieves-Favorable-Outcomes-vs-Carotid-Endarterectomy-in-Patients-with-Carotid-Artery-Disease.html

SUNNYVALE, Calif. – June 4, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

Data from the Society for Vascular Surgery’s TCAR Surveillance Project, launched in 2016 to obtain real-world comparative outcomes of TCAR and other carotid artery treatments from centers participating in the Vascular Quality Initiative (VQI), will be featured in podium and poster presentations, including:

• “Age and Outcomes After TransCarotid Artery Revascularization (TCAR), Transfemoral Carotid Artery Stenting (TF-CAS) and Carotid Endarterectomy (CEA)” (VESS14) will be presented by Dr. Hanaa Dakour Aridi of Johns Hopkins University School of Medicine during VESS Paper Session 1 on Wednesday, June 12 at 10:45 a.m. ET in Maryland D.
• “Outcomes of TransCarotid Artery Revascularization (TCAR) versus Carotid Endarterectomy (CEA) in the TCAR Surveillance Project” (SSO1) will be presented by Dr. Mahmoud Malas of the University of California, San Diego School of Medicine on Thursday, June 13 at 8:30 a.m. ET in Potomac A/B.

Read More: https://www.vasculardiseasemanagement.com/content/silk-road-medical-announces-key-tcar-presentations-society-vascular-surgery-2019-vascular